Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

708 recalls · Class II, newest first

Class II · Moderate risk

WP Thyroid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-5850-2 D-1611-2020
Class II · Moderate risk

WP Thyroid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-6050-2 D-1610-2020
Class II · Moderate risk

WP Thyroid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-5750-2 D-1609-2020
Class II · Moderate risk

WP Thyroid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-5650-2 D-1608-2020
Class II · Moderate risk

WP Thyroid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-5550-2 D-1607-2020
Class II · Moderate risk

WP Thyroid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-5450-4 D-1606-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3312-4 D-1605-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3310-4 D-1604-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3309-4 D-1603-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3308-4 D-1602-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3307-4 D-1601-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3305-4 D-1600-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3303-4 D-1599-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3299-4 D-1598-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3302-4 D-1597-2020
Class II · Moderate risk

Nature-Throid

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

Terminated Wrong potency / content RLC Labs Inc. NDC 64727-3300-4 D-1596-2020
Class II · Moderate risk

Cephalexin for Oral Suspension

CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.

Terminated cGMP deviation Teva Pharmaceuticals USA NDC 0093-4177-73 D-0013-2021
Class II · Moderate risk

Cephalexin for Oral Suspension

CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.

Terminated cGMP deviation Teva Pharmaceuticals USA NDC 0093-4175-73 D-0012-2021

Recalls by year